Tradipitant is a clinical-stage drug being developed for the treatment of Motion sickness happens when your brain gets mixed signals about movement from your eyes, inner ears, and body. When these signals don’t match, the brain thinks something is wrong and reacts with symptoms like nausea, vomiting, dizziness, cold sweats, pale skin, extra saliva, headache, tiredness, and an overall sick feeling. It usually occurs only while you’re in motion, such as during car trips, boat rides, airplane turbulence, VR games, or amusement park rides.. It is being developed by Vanda Pharmaceuticals Inc.. The FDA Prescription Drug User Fee Act (PDUFA) date is December 29, 2025. Premium analysis including detailed clinical trial status, revenue predictions, and comprehensive company insights are available for members.